Utomilumab + ISA101b
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
Conditions
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Trial Timeline
Apr 4, 2018 → Nov 5, 2021
NCT ID
NCT03258008About Utomilumab + ISA101b
Utomilumab + ISA101b is a phase 2 stage product being developed by Pfizer for Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites. The current trial status is terminated. This product is registered under clinical trial identifier NCT03258008. Target conditions include Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03258008 | Phase 2 | Terminated |
Competing Products
20 competing products in Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites